Results for tag: "Andexxa"

Andexxa is a hematological drug used to reverse the effects of Factor Xa inhibitors, a class of anticoagulants used to treat and prevent blood clots. It is a recombinant modified human Factor Xa (FXa) protein, which binds to and reverses the anticoagulant activity of Factor Xa inhibitors. It is administered as an intravenous bolus injection and is approved for use in adults with acute major bleeding episodes associated with Factor Xa inhibitor therapy. The Andexxa market is a rapidly growing segment of the hematological drugs market. It is driven by the increasing prevalence of blood clots, the growing use of Factor Xa inhibitors, and the need for a safe and effective reversal agent. The market is expected to continue to grow in the coming years, driven by the increasing prevalence of blood clots, the growing use of Factor Xa inhibitors, and the need for a safe and effective reversal agent. Some of the major companies in the Andexxa market include Portola Pharmaceuticals, Inc., Bayer AG, Pfizer Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Ltd. Show Less Read more